Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/23618

Title: Drugs, doses, and durations of intraperitoneal chemotherapy: standardizing HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma.
Authors: Lemoine, Lieselotte
Sugarbaker, Paul
Van der Speeten, Kurt
Issue Date: 2017
Status: In Press
Abstract: Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardization regarding the CRS, we are still lacking a much-needed standardization amongst the various IP chemotherapy treatment modalities used today in clinical practice. Pharmacologic evidence should be generated to answer important questions raised by the myriad of variables associated with IP chemotherapy.
Notes: Van der Speeten, K (reprint author), Ziekenhuis Oost Limburg, Dept Surg Oncol, Schiepse Bos 6, B-3600 Genk, Belgium kurt.vanderspeeten@zol.be
URI: http://hdl.handle.net/1942/23618
DOI: 10.1080/02656736.2017.1291999
ISI #: 000404780700014
ISSN: 0265-6736
Category: A1
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Peer-reviewed author version1.12 MBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.